# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001714899-25-000087
Filing Date
2025-04-17
Accepted
2025-04-17 16:05:24
Documents
26
Period of Report
2024-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | dnli-20250417.htm iXBRL | DEF 14A | 1129774
6 |  | dnli-20250417_g1.jpg | GRAPHIC | 26538
7 |  | dnli-20250417_g10.jpg | GRAPHIC | 204710
8 |  | dnli-20250417_g2.jpg | GRAPHIC | 12023
9 |  | dnli-20250417_g3.jpg | GRAPHIC | 16783
10 |  | dnli-20250417_g4.jpg | GRAPHIC | 15697
11 |  | dnli-20250417_g5.jpg | GRAPHIC | 19971
12 |  | dnli-20250417_g6.jpg | GRAPHIC | 295114
13 |  | dnli-20250417_g7.jpg | GRAPHIC | 120904
14 |  | dnli-20250417_g8.jpg | GRAPHIC | 113363
15 |  | dnli-20250417_g9.jpg | GRAPHIC | 469629
| Complete submission text file | 0001714899-25-000087.txt |  | 5009327

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
2 | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | dnli-20250417.xsd | EX-101.SCH | 4624
3 | XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT | dnli-20250417_def.xml | EX-101.DEF | 2983
4 | XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT | dnli-20250417_lab.xml | EX-101.LAB | 8664
5 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT | dnli-20250417_pre.xml | EX-101.PRE | 5967
28 | EXTRACTED XBRL INSTANCE DOCUMENT | dnli-20250417_htm.xml | XML | 220266

Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8547
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38311 | Film No.: 25847278
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)